Following the recent setback from the E-FIT trial causing shares to fall significantly, Nexstim has decided to exit stroke and instead to focus its capacities on its existing diagnostic and therapeutic business lines. As a result, we have lowered our target price. Considering current trading levels we believe the shares represent an asymmetric risk profile. In our view, the diagnostics segment represents a solid valuation floor with limited downside risk and potential for market expansion. Given ....
11 Oct 2018
Current trading levels below the valuation floor
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Current trading levels below the valuation floor
Following the recent setback from the E-FIT trial causing shares to fall significantly, Nexstim has decided to exit stroke and instead to focus its capacities on its existing diagnostic and therapeutic business lines. As a result, we have lowered our target price. Considering current trading levels we believe the shares represent an asymmetric risk profile. In our view, the diagnostics segment represents a solid valuation floor with limited downside risk and potential for market expansion. Given ....